British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.&nbsp;

"We take the matters in China very seriously," chief executive Pascal Soriot said in a statement contained in the group's latest earnings release.&nbsp;

"If requested we will fully cooperate with the authorities. We remain committed to delivering innovative life-changing medicines to patients in China," he added.

The group last week confirmed Leon Wang, president of AstraZeneca China, had been detained.

China is a key market for AstraZeneca, developer of a Covid-19 jab widely administered throughout the world during the coronavirus pandemic.

AstraZeneca on Tuesday noted that China accounted for about 12 percent of its global revenues in the third quarter. Sales in the country jumped 15 percent in the July-September period.

Also read |&nbsp;<a href="https://www.wionews.com/world/victorian-man-tricks-wife-to-leave-australia-jailed-for-exit-trafficking-775473">Victorian man tricks wife to leave Australia, jailed for exit trafficking</a>

"The company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees," the drugs giant added in the latest statement.

"To the best of the company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches."&nbsp;

AstraZeneca said it "has not received any notification that it is itself under investigation".

The probes involved five current and former employees of the firm -- all with Chinese citizenship -- who are being led by authorities in the southern city of Shenzhen, according to Bloomberg.

One investigation related to the firm's collection of patient data, which authorities suspect may have breached Chinese privacy laws, the financial newswire also reported, citing people with knowledge of the situation.

Another probe related to imports of a liver cancer drug that had not been approved in mainland China, according to Bloomberg.

Also read |&nbsp;<a href="https://www.wionews.com/world/mauritius-opposition-leader-claims-sweeping-vote-win-775465">Mauritius opposition leader claims sweeping vote win</a>

UK-headquartered AstraZeneca has 90,000 employees globally.

Global firms have faced an increasingly difficult business environment in China in recent years, industry groups say, citing a lack of transparency on data laws and prolonged detentions of employees.

Disclaimer: This story has been published from a news agency feed with minimal edits to adhere to WION's style guide. The headline may have been changed to better reflect the content of the story or to make it more suitable for WION audience.

British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.

British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss. "We take the matters in China very seriously," chief executive Pascal Soriot said in a statement contained in the group's latest earnings release. "If requested we will fully cooperate with the authorities. We remain committed to delivering innovative life-changing medicines to patients in China," he added. The group last week confirmed Leon Wang, president of AstraZeneca China, had been detained. China is a key market for AstraZeneca, developer of a Covid-19 jab widely administered throughout the world during the coronavirus pandemic. AstraZeneca on Tuesday noted that China accounted for about 12 percent of its global revenues in the third quarter. Sales in the country jumped 15 percent in the July-September period. Also read | Victorian man tricks wife to leave Australia, jailed for exit trafficking "The company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees," the drugs giant added in the latest statement. "To the best of the company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches." AstraZeneca said it "has not received any notification that it is itself under investigation". The probes involved five current and former employees of the firm -- all with Chinese citizenship -- who are being led by authorities in the southern city of Shenzhen, according to Bloomberg. One investigation related to the firm's collection of patient data, which authorities suspect may have breached Chinese privacy laws, the financial newswire also reported, citing people with knowledge of the situation. Another probe related to imports of a liver cancer drug that had not been approved in mainland China, according to Bloomberg. Also read | Mauritius opposition leader claims sweeping vote win UK-headquartered AstraZeneca has 90,000 employees globally. Global firms have faced an increasingly difficult business environment in China in recent years, industry groups say, citing a lack of transparency on data laws and prolonged detentions of employees. Disclaimer: This story has been published from a news agency feed with minimal edits to adhere to WION's style guide. The headline may have been changed to better reflect the content of the story or to make it more suitable for WION audience.

Pharma giant AstraZeneca takes China probes 'very seriously'

Pharmaceutical company AstraZeneca, led by CEO Pascal Soriot, has issued a warning about the detrimental effects of climate change and biodiversity loss on both the planet and human health. In response, the company has unveiled a groundbreaking plan to invest $400 million&nbsp;in planting 200 million trees by 2030.

Expanding on their existing tree-planting initiative, AstraZeneca aims to contribute significantly to global reforestation efforts.

The company had previously pledged to plant and maintain over 50 million trees by the end of 2025, with successful plantations already established in Australia, Indonesia, Ghana, the UK, the US, and France, reported the Guardian.&nbsp;

The newly announced program will see AstraZeneca's investment focus on reforestation, ensuring the long-term survival of the trees.

Plantations will be established in Brazil, Vietnam, Ghana, Rwanda, and India, with a particular emphasis on countries with tropical forests, such as Brazil and Indonesia, known for their carbon absorption capabilities crucial in the fight against global warming.

The urgency of these efforts is underscored by the alarming rates of deforestation observed in recent years. Despite world leaders pledging to halt deforestation at the CopP26 summit in 2021, an area equivalent to the size of Switzerland was cleared from pristine rainforests in 2022.

The tropics alone experienced a 10 per cent increase in forest loss compared to the previous year, resulting in a staggering 2.7 gigatonnes of carbon dioxide emissions—equivalent to India's annual fossil fuel emissions.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/data-lab-making-sense-of-indias-forest-cover-change-both-gains-and-losses-579663">Data Lab: Making sense of India's forest cover change, both gains and losses</a>

<h2>Carbon offset programme aims to remove 30m tonnes of CO2 from the atmosphere</h2>

AstraZeneca estimates that its tree-planting program will remove approximately 30 million tonnes of carbon dioxide from the atmosphere, playing a significant role in the company's commitment to achieving net-zero emissions by 2045.

To ensure transparency and prevent double-counting of carbon credits, AstraZeneca will share the credits with the governments of the respective countries where the trees are planted.

While carbon offsetting initiatives have come under scrutiny for their effectiveness, AstraZeneca's tree-planting projects aim to create tangible benefits.

The company plans to generate employment opportunities for local communities, supporting up to 80,000 livelihoods. Collaborating with NGOs and subjecting the projects to independent audits and assessments by experts, including the European Forest Institute, AstraZeneca demonstrates its commitment to responsible and impactful reforestation efforts.

Also watch |&nbsp;Symbolic 'cotton tree' destroyed in storm

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/symbolic-cotton-tree-destroyed-in-storm-597906/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Emphasising the importance of ecological restoration and biodiversity, CEO Pascal Soriot emphasised that AstraZeneca's program goes beyond planting identical trees in straight rows.

With a diverse range of 300 tree and plant species, the company aims to restore forests to their original state, adapting the approach to the unique characteristics of each country and region.

To ensure the success of these projects, AstraZeneca will employ innovative techniques such as drone assessments and high-resolution satellite imagery to monitor tree growth, health, and their impact on water, soil, and carbon stocks.

&nbsp;

WATCH WION LIVE HERE:

<iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed" style="width:100%;max-width:560px;" width="560"></iframe>

Pharmaceutical company AstraZeneca, led by CEO Pascal Soriot, has issued a warning about the detrimental effects of climate change and biodiversity loss on both the planet and human health.

Pharmaceutical company AstraZeneca, led by CEO Pascal Soriot, has issued a warning about the detrimental effects of climate change and biodiversity loss on both the planet and human health. In response, the company has unveiled a groundbreaking plan to invest $400 million in planting 200 million trees by 2030. Expanding on their existing tree-planting initiative, AstraZeneca aims to contribute significantly to global reforestation efforts. The company had previously pledged to plant and maintain over 50 million trees by the end of 2025, with successful plantations already established in Australia, Indonesia, Ghana, the UK, the US, and France, reported the Guardian. The newly announced program will see AstraZeneca's investment focus on reforestation, ensuring the long-term survival of the trees. Plantations will be established in Brazil, Vietnam, Ghana, Rwanda, and India, with a particular emphasis on countries with tropical forests, such as Brazil and Indonesia, known for their carbon absorption capabilities crucial in the fight against global warming. The urgency of these efforts is underscored by the alarming rates of deforestation observed in recent years. Despite world leaders pledging to halt deforestation at the CopP26 summit in 2021, an area equivalent to the size of Switzerland was cleared from pristine rainforests in 2022. The tropics alone experienced a 10 per cent increase in forest loss compared to the previous year, resulting in a staggering 2.7 gigatonnes of carbon dioxide emissions—equivalent to India's annual fossil fuel emissions. Also read | Data Lab: Making sense of India's forest cover change, both gains and losses Carbon offset programme aims to remove 30m tonnes of CO2 from the atmosphere AstraZeneca estimates that its tree-planting program will remove approximately 30 million tonnes of carbon dioxide from the atmosphere, playing a significant role in the company's commitment to achieving net-zero emissions by 2045. To ensure transparency and prevent double-counting of carbon credits, AstraZeneca will share the credits with the governments of the respective countries where the trees are planted. While carbon offsetting initiatives have come under scrutiny for their effectiveness, AstraZeneca's tree-planting projects aim to create tangible benefits. The company plans to generate employment opportunities for local communities, supporting up to 80,000 livelihoods. Collaborating with NGOs and subjecting the projects to independent audits and assessments by experts, including the European Forest Institute, AstraZeneca demonstrates its commitment to responsible and impactful reforestation efforts. Also watch | Symbolic 'cotton tree' destroyed in storm Emphasising the importance of ecological restoration and biodiversity, CEO Pascal Soriot emphasised that AstraZeneca's program goes beyond planting identical trees in straight rows. With a diverse range of 300 tree and plant species, the company aims to restore forests to their original state, adapting the approach to the unique characteristics of each country and region. To ensure the success of these projects, AstraZeneca will employ innovative techniques such as drone assessments and high-resolution satellite imagery to monitor tree growth, health, and their impact on water, soil, and carbon stocks. WATCH WION LIVE HERE:

AstraZeneca launches $400mn tree-planting initiative to combat climate change, biodiversity loss

People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden.

Since the use of AstraZeneca's vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose.

Also Read |&nbsp;<a href="https://www.wionews.com/world/sydney-eases-more-covid-19-curbs-as-vaccinations-pass-milestone-421652">Sydney eases more COVID-19 curbs as vaccinations pass milestone</a>

"Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one," said Peter Nordstrom, a professor at Umea University, Sweden.

"However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses," Nordstrom said.

The study, published in The Lancet Regional Health - Europe journal on Monday, is based on nationwide registry data from the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden.

Also Read |&nbsp;<a href="https://www.wionews.com/india-news/covid-19-covaxin-gets-emergency-use-nod-for-children-aged-2-18-years-420111">COVID-19: Covaxin gets emergency use nod for children aged 2-18 years</a>

In the main analysis, about 700,000 individuals were included. During a 2.5-month average follow-up period after the second dose, the study showed a 67 per cent lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots.

There was a 79 per cent lower risk of infection for AstraZeneca and Moderna vaccine shots, compared to unvaccinated individuals, the researchers said.

For people having received two doses of the AstraZeneca vaccine, known as Covishield in India, the risk reduction was 50, they said.

These risk estimates were observed after accounting for differences regarding date of vaccination, age of the participants, socioeconomic status, and other risk factors for COVID-19.

The researchers noted that the study estimates of effectiveness apply to infection with the Delta variant, which was dominating the confirmed cases during the follow-up period.

"The results of the study may have implications for vaccination strategies in different countries," said Marcel Ballin, doctoral student at Umea University, and co-author of the study.

Also Read |&nbsp;<a href="https://www.wionews.com/world/us-experts-recommend-moderna-booster-for-older-and-at-risk-groups-420849">US experts recommend Moderna booster for older and at-risk groups</a>

"The World Health Organization has stated that despite the promising results from previous studies regarding immune response from mix-and-match vaccination, there is a need for larger studies to investigate their safety and effectiveness against clinical outcomes. Here we now have one such study," Ballin said.

There was a very low incidence of adverse thromboembolic events, or formation of blood clots in blood vessels, for all vaccine schedules, according to the researchers.

The number of COVID-19 cases severe enough to result in inpatient hospitalisation was too low for the researchers to be able to calculate the effectiveness against this outcome.

Past studies have demonstrated that mix-and-match vaccine schedules generate a robust immune response.

However, it has been unclear to which extent these schedules may reduce the risk of clinical infection, the researchers said, adding that their study aimed to fill that knowledge gap.

People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden.

People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden. Since the use of AstraZeneca's vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose. Also Read | Sydney eases more COVID-19 curbs as vaccinations pass milestone "Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one," said Peter Nordstrom, a professor at Umea University, Sweden. "However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses," Nordstrom said. The study, published in The Lancet Regional Health - Europe journal on Monday, is based on nationwide registry data from the Public Health Agency of Sweden, the National Board of Health and Welfare, and Statistics Sweden. Also Read | COVID-19: Covaxin gets emergency use nod for children aged 2-18 years In the main analysis, about 700,000 individuals were included. During a 2.5-month average follow-up period after the second dose, the study showed a 67 per cent lower risk of infection for the combination of AstraZeneca and Pfizer vaccine shots. There was a 79 per cent lower risk of infection for AstraZeneca and Moderna vaccine shots, compared to unvaccinated individuals, the researchers said. For people having received two doses of the AstraZeneca vaccine, known as Covishield in India, the risk reduction was 50, they said. These risk estimates were observed after accounting for differences regarding date of vaccination, age of the participants, socioeconomic status, and other risk factors for COVID-19. The researchers noted that the study estimates of effectiveness apply to infection with the Delta variant, which was dominating the confirmed cases during the follow-up period. "The results of the study may have implications for vaccination strategies in different countries," said Marcel Ballin, doctoral student at Umea University, and co-author of the study. Also Read | US experts recommend Moderna booster for older and at-risk groups "The World Health Organization has stated that despite the promising results from previous studies regarding immune response from mix-and-match vaccination, there is a need for larger studies to investigate their safety and effectiveness against clinical outcomes. Here we now have one such study," Ballin said. There was a very low incidence of adverse thromboembolic events, or formation of blood clots in blood vessels, for all vaccine schedules, according to the researchers. The number of COVID-19 cases severe enough to result in inpatient hospitalisation was too low for the researchers to be able to calculate the effectiveness against this outcome. Past studies have demonstrated that mix-and-match vaccine schedules generate a robust immune response. However, it has been unclear to which extent these schedules may reduce the risk of clinical infection, the researchers said, adding that their study aimed to fill that knowledge gap.

Mix-and-match vaccines highly effective against COVID-19: Lancet study

Russian spies allegedly acquired the design for the life-saving Oxford/AstraZeneca jab and utilised it to construct their own Sputnik V jab and win the race to produce the world's first effective coronavirus vaccine. However, Sputnik V has refuted these claims as "old fake news".

Security sources are said to have told UK ministers that they had proof that Kremlin agents stole the Covid vaccine plan and used it to create their own vaccine.

As per The Sun, the vaccine blueprint and crucial documents were stolen in person by a foreign spy. 
 
<a href="https://www.wionews.com/world/russian-president-vladimir-putin-says-several-dozen-people-within-the-kremlin-inner-circle-have-covid-19-413605">Also read | Russian president Vladimir Putin says 'several dozen people' within the Kremlin inner circle have COVID-19&nbsp;</a>

However, a&nbsp;press release by the vaccine manufacturer labels the news reports a "blatant lie based on anonymous sources". It goes on to say that this is merely an attempt "by those opposing the success of one of the world’s most effective and safe vaccines against COVID-19" adding that they find attacks like these "highly unethical as they undermine the global vaccination effort".

Addressing the viral claims, they also sent out a tweet that said, "UK tabloids are again pushing old fake news about “stolen” technology. #SputnikV is based on human adenoviral platform designed 7 years ago, very different from AstraZeneca vaccine, based on chimpanzee adenovirus. Lies in media undermine global partnership to fight #COVID."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
UK tabloids are again pushing old fake news about “stolen” technology. <a href="https://twitter.com/hashtag/SputnikV?src=hash&amp;ref_src=twsrc%5Etfw">#SputnikV</a> is based on human adenoviral platform designed 7 years ago, very different from AstraZeneca vaccine, based on chimpanzee adenovirus. 
Lies in media undermine global partnership to fight <a href="https://twitter.com/hashtag/COVID?src=hash&amp;ref_src=twsrc%5Etfw">#COVID</a>.
— Sputnik V (@sputnikvaccine) <a href="https://twitter.com/sputnikvaccine/status/1447550194757820431?ref_src=twsrc%5Etfw">October 11, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

They added that "rather than spreading fake stories, the UK media and government services should better protect the reputation of AstraZeneca, a safe and efficient vaccine that is constantly attacked by competitors in the media with facts taken out of&nbsp;context."

Watch | Gravitas: India approves Russia's Sputnik-V vaccine

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-india-approves-russias-sputnik-v-vaccine-377159/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<div class="videoWrapper trancodeVideo">&nbsp;</div>

<div class="videoWrapper trancodeVideo">According to the security sources claims, a Moscow mole in the UK physically obtained the highly secret design, although&nbsp;it is unclear if this was a paper from the pharma giant's lab or factory or a vial of the final drug smuggled out of the country for examination.</div>

<div class="videoWrapper trancodeVideo">&nbsp;</div>

<div class="videoWrapper trancodeVideo">Also read |&nbsp;<a href="https://www.wionews.com/world/vaccines-prevent-severe-covid-even-from-delta-study-419798">Vaccines prevent severe Covid, even from Delta: study</a></div>

MI5 operatives have previously stated that Russian hackers attempted multiple cyber strikes on Oxford University beginning in March 2020, around a month after British scientists revealed they had begun researching a vaccine.&nbsp;

Damian Hinds, the UK Security Minister, declined to corroborate the accusation but claims that&nbsp;cyber-assaults were growing more sophisticated.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/astrazenecas-new-vaccine-trial-aims-to-treat-severe-covid-19-symptoms-419971">AstraZeneca's new vaccine trial aims to treat severe COVID-19 symptoms</a>

Oxford/AZ announced the start of the first human trials in April of last year, but Moscow announced the following month that they had invented their own vaccine, and by August, Vladimir Putin gave a TV address to the Russian people declaring that Russia had won the global race to develop the first Covid-19 vaccine.

It was eventually discovered that Sputnik V operates in the same manner as its British cousin, both are viral vector vaccines, which means they employ a latent virus to transport the immune agent that ultimately destroys the coronavirus.

(With inputs from agencies)

Russian spies allegedly acquired the design for the life-saving Oxford/AstraZeneca jab and utilised it to construct their own Sputnik V jab and win the race to produce the world's first effective coronavirus vaccine.

Russian spies allegedly acquired the design for the life-saving Oxford/AstraZeneca jab and utilised it to construct their own Sputnik V jab and win the race to produce the world's first effective coronavirus vaccine. However, Sputnik V has refuted these claims as "old fake news". Security sources are said to have told UK ministers that they had proof that Kremlin agents stole the Covid vaccine plan and used it to create their own vaccine. As per The Sun, the vaccine blueprint and crucial documents were stolen in person by a foreign spy. Also read | Russian president Vladimir Putin says 'several dozen people' within the Kremlin inner circle have COVID-19 However, a press release by the vaccine manufacturer labels the news reports a "blatant lie based on anonymous sources". It goes on to say that this is merely an attempt "by those opposing the success of one of the world’s most effective and safe vaccines against COVID-19" adding that they find attacks like these "highly unethical as they undermine the global vaccination effort". Addressing the viral claims, they also sent out a tweet that said, "UK tabloids are again pushing old fake news about “stolen” technology. #SputnikV is based on human adenoviral platform designed 7 years ago, very different from AstraZeneca vaccine, based on chimpanzee adenovirus. Lies in media undermine global partnership to fight #COVID." UK tabloids are again pushing old fake news about “stolen” technology. #SputnikV is based on human adenoviral platform designed 7 years ago, very different from AstraZeneca vaccine, based on chimpanzee adenovirus. Lies in media undermine global partnership to fight #COVID. — Sputnik V (@sputnikvaccine) October 11, 2021 × They added that "rather than spreading fake stories, the UK media and government services should better protect the reputation of AstraZeneca, a safe and efficient vaccine that is constantly attacked by competitors in the media with facts taken out of context." Watch | Gravitas: India approves Russia's Sputnik-V vaccine According to the security sources claims, a Moscow mole in the UK physically obtained the highly secret design, although it is unclear if this was a paper from the pharma giant's lab or factory or a vial of the final drug smuggled out of the country for examination. Also read | Vaccines prevent severe Covid, even from Delta: study MI5 operatives have previously stated that Russian hackers attempted multiple cyber strikes on Oxford University beginning in March 2020, around a month after British scientists revealed they had begun researching a vaccine. Damian Hinds, the UK Security Minister, declined to corroborate the accusation but claims that cyber-assaults were growing more sophisticated. Also read | AstraZeneca's new vaccine trial aims to treat severe COVID-19 symptoms Oxford/AZ announced the start of the first human trials in April of last year, but Moscow announced the following month that they had invented their own vaccine, and by August, Vladimir Putin gave a TV address to the Russian people declaring that Russia had won the global race to develop the first Covid-19 vaccine. It was eventually discovered that Sputnik V operates in the same manner as its British cousin, both are viral vector vaccines, which means they employ a latent virus to transport the immune agent that ultimately destroys the coronavirus. (With inputs from agencies)

'Old fake news': Sputnik V refutes claims Russia stole Oxford vaccine blueprint

On Monday, the British pharmaceutical firm AstraZeneca announced positive results from a third phase trial aimed at treating symptoms of COVID-19.

According to AstraZeneca, the drug&nbsp;which is a combination of two antibodies created a statistically significant reduction in severe COVID-19 symptoms or death in non-hospitalized patients with mild-to-moderate symptoms. &nbsp;

Also read | <a href="https://www.wionews.com/world/russia-stole-blueprint-for-oxford-covid-vaccine-to-create-sputnik-v-sources-419855">Russia stole blueprint for Oxford Covid vaccine to create Sputnik V: Sources</a>

A total of 903 participants were involved in the trial, 90 per cent of whom were at high risk of progressing to severe <a href="https://www.wionews.com/topics/coronavirus">COVID-19</a>.

As per the information available on the AstraZeneca website, an analysis of participants treated within five days of symptoms onset found that "AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 67%."&nbsp;&nbsp;

Watch | United Nations, World Health Organization come together for a collective goal

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/united-nations-world-health-organisation-come-together-for-a-collective-goal-419030/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Final clinical trials or phase three trials are being conducted on the treatment, also known as AZD7442, to determine its safety and effectiveness.

"With continued cases of serious COVID-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations ... and can also help prevent progression to severe disease," said Hugh Montgomery, the trial's principal investigator.

Also read | <a href="https://www.wionews.com/world/vaccines-prevent-severe-covid-even-from-delta-study-419798">Vaccines prevent severe Covid, even from Delta: study</a>

"These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic." he added.

In Britain, AstraZeneca's separate Covid vaccine, developed in partnership with Oxford University, contributed to the quick response to the Covid threat.

(With inputs from agencies)

&nbsp;

On Monday, the British pharmaceutical firm AstraZeneca announced positive results from a third phase trial aimed at treating symptoms of COVID-19. According to AstraZeneca, the drug which is a combination of two antibodies created a statistically significant reduction in severe COVID-19 symptoms or death in non-hospitalized patients with mild-to-moderate symptoms.

On Monday, the British pharmaceutical firm AstraZeneca announced positive results from a third phase trial aimed at treating symptoms of COVID-19. According to AstraZeneca, the drug which is a combination of two antibodies created a statistically significant reduction in severe COVID-19 symptoms or death in non-hospitalized patients with mild-to-moderate symptoms. Also read | Russia stole blueprint for Oxford Covid vaccine to create Sputnik V: Sources A total of 903 participants were involved in the trial, 90 per cent of whom were at high risk of progressing to severe COVID-19. As per the information available on the AstraZeneca website, an analysis of participants treated within five days of symptoms onset found that "AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 67%." Watch | United Nations, World Health Organization come together for a collective goal Final clinical trials or phase three trials are being conducted on the treatment, also known as AZD7442, to determine its safety and effectiveness. "With continued cases of serious COVID-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations ... and can also help prevent progression to severe disease," said Hugh Montgomery, the trial's principal investigator. Also read | Vaccines prevent severe Covid, even from Delta: study "These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic." he added. In Britain, AstraZeneca's separate Covid vaccine, developed in partnership with Oxford University, contributed to the quick response to the Covid threat. (With inputs from agencies)

AstraZeneca's new vaccine trial aims to treat severe COVID-19 symptoms

Nepal on Monday rolled out second COVID-19 vaccine jabs for nearly 1.4 million elderly people. People aged over 65 became eligible to receive their first AstraZeneca-Oxford shots from March but were unable to get their second dose after the stock ran out.

Nepal rolls out second COVID-19 vaccine jabs for nearly 1.4 million elderly people

astra-zeneca

Astra Zeneca, News on Astra Zeneca, stories on Astra Zeneca, articles on Astra Zeneca, Astra Zeneca stories at Wion, Astra Zeneca news, Astra Zeneca latest news